Catalyst Pharmaceuticals, Inc. (CPRX) Earnings History
Annual and quarterly earnings data from 2004 to 2025
Loading earnings history...
CPRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CPRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 85.2% | 43.8% | 36.4% |
| 2024 | 86.0% | 39.7% | 33.3% |
| 2023 | 86.9% | 21.8% | 17.9% |
| 2022 | 83.9% | 47.5% | 38.8% |
| 2021 | 84.5% | 37.2% | 28.0% |
Download Data
Export CPRX earnings history in CSV or JSON format
Free sign-in required to download data
Catalyst Pharmaceuticals, Inc. (CPRX) Earnings Overview
As of May 8, 2026, Catalyst Pharmaceuticals, Inc. (CPRX) reported trailing twelve-month net income of $214M, reflecting +28.2% year-over-year growth. The company earned $1.68 per diluted share over the past four quarters, with a net profit margin of 36.4%.
Looking at the long-term picture, CPRX's 5-year EPS compound annual growth rate (CAGR) stands at +18.8%, indicating exceptional earnings growth. The company achieved its highest annual net income of $214M in fiscal 2025, representing a new all-time high.
Catalyst Pharmaceuticals, Inc. maintains industry-leading profitability with a gross margin of 85.2%, operating margin of 43.8%, and net margin of 36.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), CPRX has outperformed on profitability metrics. Compare CPRX vs RARE →
CPRX Earnings vs Peers
Earnings metrics vs comparable public companies
CPRX Historical Earnings Data (2004–2025)
22 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $214M | +30.8% | $258M | $1.68 | 36.4% | 43.8% |
| 2024 | $164M | +129.5% | $195M | $1.31 | 33.3% | 39.7% |
| 2023 | $71M | -14.0% | $87M | $0.63 | 17.9% | 21.8% |
| 2022 | $83M | +110.4% | $102M | $0.75 | 38.8% | 47.5% |
| 2021 | $39M | -47.3% | $52M | $0.37 | 28.0% | 37.2% |
| 2020 | $75M | +135.2% | $41M | $0.71 | 63.0% | 34.7% |
| 2019 | $32M | +193.7% | $32M | $0.30 | 31.2% | 31.1% |
| 2018 | -$34M | -84.7% | -$35M | $-0.33 | -6800.7% | -7059.0% |
| 2017 | -$18M | -1.9% | -$19M | $-0.21 | - | - |
| 2016 | -$18M | +10.7% | -$19M | $-0.22 | - | - |
See CPRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CPRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CPRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCPRX — Frequently Asked Questions
Quick answers to the most common questions about buying CPRX stock.
Is CPRX growing earnings?
CPRX EPS is $1.68, with earnings growth accelerating to +28.2%. This exceeds the 5-year CAGR of +18.8%. TTM net income reached $214M.
What are CPRX's profit margins?
Catalyst Pharmaceuticals, Inc. net margin is +36.4%, with operating margin at +43.8%. Above-average margins indicate pricing power.
How consistent are CPRX's earnings?
CPRX earnings data spans 2004-2025. The accelerating earnings trend is +28.2% YoY. Historical data enables comparison across business cycles.